Engflag

Distaval

Quick links to important sections

Distaval

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Distaval

The following section provides essential facts about the medicine Distaval (Thalidomide) by defining its nature, composition, and general classification.

Property Description
Active ingredient Thalidomide
Form Tablet (Oral formulation)
Pharmacological class Immunomodulatory drug, Sedative-hypnotic agent
Common use Aid sleep (Historical intent); Modulate immune response (Modern function)
Origin Synthetic compound

Core Composition and Identity

Distaval is the historical prescription-only medicine trade name for a product containing the synthetic compound Thalidomide as its active ingredient. This small molecule is structurally known as alpha-(N-phthalimido)glutarimide. The drug is a monotherapy, relying on Thalidomide alone, and was primarily delivered as an oral formulation in a tablet (solid dosage form).

The compound is supplied as a racemic mixture of R- and S-enantiomers, where each form contributes differently to the drug’s overall effect in the body. Distaval was uniquely positioned during its initial release in the 1950s by its original manufacturer, Chemiewerk Homburg, as an alternative to older sleep aids.

Pharmacological Classification and General Purpose

Thalidomide is defined by a dual pharmacological classification, historically recognized as a sedative-hypnotic agent before being scientifically reclassified as a potent immunomodulatory drug with antiangiogenic properties. The R-enantiomer is chiefly associated with the sedative property that was originally marketed to aid sleep, a typical use scenario for which the medicine gained prominence.

The modern understanding of its function focuses on its capacity to adjust and regulate the body’s inflammatory response. The drug's ability to inhibit and modulate inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), relates to how the medicine is systematically used to dampen severe or unwarranted inflammatory processes. The unique differentiation of Thalidomide from simple sedatives lies in this immunomodulatory mechanism.

What side effects are possible with Distaval?

Possible Side Effects and Safety Information

The safety profile of Thalidomide, the active ingredient in Distaval, is strictly regulated due to significant risks. The most critical safety constraint is the drug's classification as a potent human teratogen, leading to an absolute contraindication in pregnancy due to the high risk of severe, life-threatening birth defects.

Regulatory documents organize adverse reactions by frequency and physiological system. Very Common (ge 10% of patients) reactions often affect the Nervous System, including peripheral neuropathy (which can be irreversible), somnolence (drowsiness), dizziness, and tremor. Gastrointestinal effects like constipation are also frequently documented.

Serious adverse reactions highlighted in official labeling include an increased risk of Venous and Arterial Thromboembolism (blood clots, including deep vein thrombosis and pulmonary embolism), especially when combined with other agents like dexamethasone. Peripheral neuropathy is further noted as a dose- and duration-dependent effect, often appearing or increasing in severity after several months of continuous exposure, as documented in regulatory guidelines. Serious cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also classified as significant safety concerns.

Population-specific safety notes include the mandated use of stringent risk mitigation programs for all individuals of reproductive potential. Additionally, older adults (over 75 years) are noted to have an increased likelihood of specific adverse effects, particularly cardiac and thromboembolic issues, according to prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Distaval (Thalidomide) primarily results in manifestations of Central Nervous System (CNS) depression. Documented clinical signs include marked drowsiness, somnolence, and profound sedation. In the event of a massive acute ingestion, the condition may progress to a state of coma.

Urgent Regulatory Actions

Due to the risk of severe CNS effects, which include the life-threatening outcome of respiratory depression, official guidance mandates that individuals must seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if severe signs of CNS depression or unresponsiveness are observed.

Management and Monitoring

Regulatory prescribing information confirms that no specific antidote is known for thalidomide overdose. Therefore, management is limited to symptomatic and supportive treatment. Officially described procedural steps include maintenance of a patent airway and attention to fluid balance support. Hospital monitoring and prolonged observation are required due to the potential for delayed or protracted CNS effects, ensuring close vital sign monitoring. High or prolonged exposure also contributes to the documented risk of peripheral neuropathy.

Therapeutic Uses of Distaval

What Distaval Treats: Main Uses and Benefits

The medicine is considered relevant for easing symptoms related to inflammatory or irritative states and is commonly used in conditions where symptoms may intensify temporarily. The medication may be utilized as part of symptomatic management for conditions such as Erythema Nodosum Leprosum (ENL), certain phases of Multiple Myeloma, and HIV-associated wasting syndrome.

It is applied in clinical settings that involve acute or unstable symptom patterns, addressing painful skin manifestations, chronic mucocutaneous ulcers, and symptoms that interfere with daily functioning associated with systemic imbalance. The medication may assist with easing the overall symptom burden, particularly during difficult episodes. Historically, Distaval was also relevant for episodes associated with difficulty sleeping, offering symptomatic assistance.

“It is applied in scenarios where additional management of discomfort is required.”

Quick Fact: Support for Symptom Burden The medication contributes to improved comfort by addressing both symptoms related to physical discomfort (like severe skin lesions) and symptoms that create noticeable physiological strain (like wasting).

Regulatory References

  1. NIH MedlinePlus overview on Thalidomide

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Distaval (Thalidomide) — Official Regulatory Information

Eligibility Scope

Classification Populations & Restrictions
Populations for whom use is Contraindicated Females who are pregnant (due to severe Embryo-Fetal Toxicity). Patients with demonstrated hypersensitivity to the drug or its components.
Eligibility-Related Restrictions All patients must comply with the requirements of the mandatory Restricted Distribution Program (e.g., THALOMID REMS^ TM). Use is restricted to certified prescribers and pharmacies. Males and females must not donate blood or semen during treatment and for a specified time after discontinuation.
Age-Related Eligibility Rules Females of reproductive potential must use two acceptable forms of contraception and undergo mandatory periodic pregnancy testing. Males must use barrier contraception when engaging in sexual activity with a female of reproductive potential.
Condition-Specific Rules Treatment should not be initiated if a patient's absolute neutrophil count (ANC) is <750 /mm^3. The drug should not be resumed in patients who previously developed severe skin reactions like Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. Patients with a history of or risk factors for blood clots require close monitoring and may need prophylaxis.
Pregnancy/Lactation Status Pregnancy is Contraindicated. Breastfeeding is not recommended as the drug is present in human milk.

Connection to the Overall Eligibility Profile

The regulatory eligibility profile for Distaval (thalidomide) is defined by its powerful teratogenicity, which carries a Boxed Warning and an absolute contraindication for use in pregnant females. Consequently, all other patients (male and female) who receive the medicine must adhere strictly to a mandatory, government-monitored Risk Evaluation and Mitigation Strategy (REMS) program. This ensures strict compliance with pregnancy prevention measures and confirms that the benefits of its approved use outweigh the significant risks for the eligible, highly-restricted patient population.

What should I know about interactions with other medicines?

The interaction profile of Distaval (Thalidomide) is defined predominantly by pharmacodynamic additive effects, as noted in official government prescribing documents.

Documented Interaction Patterns

The primary concern involves substances that increase toxicity risk or diminish co-administered medication efficacy. The official documents classify these interactions into distinct categories:

  • Central Nervous System (CNS) Depressants: Co-administration with agents such as Opioids, Antihistamines, Antipsychotics, or Alcohol may result in an additive sedative effect, including increased drowsiness and dizziness.

  • Thromboembolism Risk: The combination of Thalidomide with other therapies, notably Dexamethasone, Estrogen-containing therapies, or Erythropoietin stimulating agents, significantly increases the risk of venous and arterial thromboembolism (VTE).

  • Neuropathy Risk: When used with other medicinal products known to cause peripheral neuropathy, there is a documented increased risk and/or severity of nerve damage.

  • Contraceptive Efficacy: Although pharmacokinetic interactions with hormonal contraceptives are not typically anticipated, the regulatory documentation requires women of childbearing potential to use two reliable forms of contraception simultaneously due to the potential for reduced hormonal contraceptive efficacy and the potential for increased VTE risk.

  • Other Specific Interactions: Close monitoring of the International Normalized Ratio (INR) is required when co-administered with Warfarin. In patients with HIV infection, an increase in plasma viral RNA levels has been noted, and viral load monitoring is recommended. The combination with Pembrolizumab and Dexamethasone has resulted in increased mortality in a specific patient population, leading to a regulatory restriction.

Mechanism of Action

The action of Thalidomide (Distaval) is defined by three distinct mechanisms that modulate physiological processes, particularly those involving the immune system and cell growth. The primary action is Molecular Glue Modulation, where the drug binds directly to the cellular protein Cereblon ( CRBN), a component of the E3 ubiquitin ligase system. The binding event causes Thalidomide to act as a molecular glue modulator, forcing the CRBN complex to tag specific immune cell proteins, such as IKZF1 and IKZF3, for targeted destruction. This action alters the immune response and T-cell activity, leading to a modification of inflammatory pathway signaling. A simultaneous mechanism involves Post-transcriptional Anti-Inflammatory Control: the drug acts as an inhibitor of the pro-inflammatory cytokine Tumor Necrosis Factor-alpha ( TNF-alpha) by accelerating the degradation of its messenger RNA ( mRNA). This restricts the concentration of circulating mediators and results in an anti-angiogenic (inhibition of new blood vessel formation) physiological consequence. Finally, the drug is a racemic mixture. The R-enantiomer is linked to a CRBN-independent central nervous system ( CNS) depression, leading to a sedative physiological state. However, the two chemical forms racemize (interconvert) rapidly within the body, making the sedative effect mechanistically inseparable from the CRBN-mediated effects.

Dosage and Administration Information

How to use Distaval

Thalidomide, historically marketed as Distaval, is prescribed for oral administration only and is supplied as a capsule or tablet. The usage protocol mandates that the medicine must be swallowed whole with water; the product must not be opened, crushed, or chewed. This non-crushing constraint is a fundamental rule for administration.

Dosing and Scheduling Principles

The dosage is dependent on the condition, following specific guidelines. For Multiple Myeloma, the standard adult starting dose is typically 200 mg once daily. For Erythema Nodosum Leprosum (ENL), the initial dose ranges from 100 mg to 300 mg per day, with the option to increase up to 400 mg/day for severe manifestations. The single daily dose is consistently administered at bedtime, preferably at least one hour after the evening meal, a timing rule intended to support consistent systemic exposure.

Use is structured either in fixed cycles (e.g., 28-day treatment cycles for Multiple Myeloma) or via a tapering phase. For ENL, once active symptoms subside, the use involves a gradual dose reduction until the minimum maintenance level is reached, with attempts to taper off the medication entirely occurring every three to six months.

Procedural Administration Rules

Established instructions specify adjustments for certain populations; for instance, the starting dose for older adults (age ge 75) being treated for Multiple Myeloma may be set at 100 mg per day. A key procedural rule for all patients is the management of a missed dose: if a scheduled dose is missed, it must not be taken, and the patient should resume the regimen with the next scheduled dose at the usual time. This structured protocol defines the standardized operational pattern for use.

Recent Clinical Evidence

Evidence for Use in Erythema Nodosum Leprosum (ENL)

Distaval was studied for conditions characterized by fluctuating manifestations of ENL using older Randomized Controlled Trials (RCTs) and patient record analyses. These studies monitored outcomes related to physical discomfort, such as the severity of skin lesions and the rate of clinical recovery. Studies reported patterns observed in the evolution of ENL manifestations in some cohorts, and research examined patterns associated with corticosteroid co-intervention. However, evidence is limited for long-term outcomes and the prevention of recurrence, and the evidence quality varies across studies.

Evidence for Use in Multiple Myeloma (MM)

Research was conducted using Distaval for Multiple Myeloma, primarily through large Phase III Clinical Trials and meta-analyses. These studies monitored outcomes related to Overall Survival (OS) and Progression-Free Survival (PFS), typically when the medicine was evaluated in combination with other chemotherapy agents. Data show patterns related to Progression-Free Survival (PFS) and Overall Response Rates (ORR) in patients receiving specific treatment combinations. The majority of evidence comes from combination treatment, meaning there is limited information on monotherapy. Subgroup findings are uncertain for patients with specific genetic features.

Evidence for Use in HIV-Associated Wasting Syndrome

Distaval was observed in short-term, placebo-controlled trials focusing on outcomes related to systemic or functional imbalance, specifically changes in body weight and fat-free mass. Studies report how patient measurements evolved in the observed populations. However, this evidence was collected predominantly during the era before modern, highly effective antiretroviral therapy (ART) was standard. Consequently, follow-up durations were limited, and the applicability of these results to current patients is uncertain.

Research Gaps and Limitations

The available research provides context but not individual predictions regarding long-term health. Evidence is limited for long-term outcomes for all indications, particularly concerning the durability of any observed changes. Research has been conducted on older adults, but data for certain groups, such as children, remain insufficient across all indications. The results apply only to the populations studied in the original clinical trials, and research is ongoing to further contextualize the role of Distaval in modern treatment landscapes.

Key Studies & References Thalidomide (MedlinePlus Drug Information) - NIH

Frequently Asked Questions (FAQ)

Common questions about Distaval (FAQ)

Q: How long do I have to continue using contraception after stopping Distaval?

Regulatory documents state that females of reproductive potential must continue using two acceptable forms of contraception for at least four weeks after taking the last dose. For males, official regulatory guidance indicates the need to use barrier contraception for a specified period after discontinuing treatment.

Q: How is Distaval thought to treat Erythema Nodosum Leprosum (ENL)?

Official information indicates that Distaval is thought to treat the symptoms of ENL due to its anti-inflammatory properties. Research suggests the drug may act by inhibiting the overproduction of specific inflammatory chemicals in the body, such as Tumor Necrosis Factor-alpha (TNF-alpha).

Q: How does Distaval interact with alcohol?

Co-administering Distaval with alcohol is associated with an increased risk of an additive sedative effect. Official prescribing information notes that this combination may result in increased drowsiness and dizziness, which can impair a person's physical and mental abilities.

Q: Is peripheral neuropathy reversible after I stop taking Distaval?

Official safety information notes that peripheral neuropathy (nerve damage) is a potentially severe side effect of Distaval. Peripheral neuropathy may persist after discontinuation, and regulatory documents note that the condition can be irreversible.

Q: Can Distaval be split in half if the dose needs to be adjusted?

No. Product labeling states that the capsule or tablet must be swallowed whole with water. The administration instructions require that the product must not be opened, crushed, chewed, or otherwise manipulated.

Q: Can Distaval interact with grapefruit juice?

Official pharmacological studies do not typically show that this drug is significantly affected by the enzyme system (Cytochrome P450) that causes many common grapefruit-drug interactions. However, official documents do not cite a specific clinical interaction study with grapefruit.

Q: Is Distaval (Thalidomide) a chemotherapy drug?

The official classification of Distaval (Thalidomide) is as an immunomodulatory agent, meaning it helps regulate the immune system. Although it is commonly used in combination with other agents to treat the cancer Multiple Myeloma, it is not classified by regulatory sources solely as a cytotoxic chemotherapy drug.

Q: What happens if my ANC count drops below 750/mm^3 during treatment?

Official prescribing documents include specific guidelines for managing a low Absolute Neutrophil Count (ANC), a condition called neutropenia, that occurs during therapy. These instructions detail necessary dose modifications, which may involve temporarily suspending or reducing the amount of the drug being taken.

How should Distaval be stored and disposed of?

How to Store and Dispose of Distaval

The storage and disposal of Distaval (thalidomide) are subject to official regulatory requirements to ensure product integrity and manage safety risks.

Storage Conditions

Distaval must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and stored away from excessive heat or moisture. For safety, the product must be kept out of the reach of children and pets, and official labeling recommends storing it locked up.

Handling and Container Rules

The medicine must remain in its original container and be kept in its blister pack until the time of use. Capsules must not be crushed, opened, or chewed. If the powder contacts skin or mucous membranes, the affected area must be washed immediately.

Official Disposal Instructions

Unused or expired Distaval must not be disposed of in household trash or flushed down the toilet. Due to regulatory requirements, the product must be returned to a pharmacist or healthcare provider through an official drug take-back or mail-back program for regulated disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Distaval found in:

A-Z Index: